Cargando…
Engineering better chimeric antigen receptor T cells
CD19-targeted CAR T cells therapy has shown remarkable efficacy in treatment of B cell malignancies. However, relapse of primary disease remains a major obstacle after CAR T cells therapy, and the majority of relapses present a tumor phenotype with retention of target antigen (antigen-positive relap...
Autores principales: | Zhang, Hao, Zhao, Pu, Huang, He |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709221/ https://www.ncbi.nlm.nih.gov/pubmed/33292660 http://dx.doi.org/10.1186/s40164-020-00190-2 |
Ejemplares similares
-
Engineering chimeric antigen receptor T cells for solid tumour therapy
por: Liu, Longwei, et al.
Publicado: (2022) -
Engineering chimeric antigen receptor-T cells for cancer treatment
por: Ye, Baixin, et al.
Publicado: (2018) -
Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer
por: Cartellieri, Marc, et al.
Publicado: (2010) -
Engineering Chimeric Antigen Receptors
por: Kulemzin, S. V., et al.
Publicado: (2017) -
Engineering Solutions for Mitigation of Chimeric Antigen Receptor T-Cell Dysfunction
por: Gavriil, Artemis, et al.
Publicado: (2020)